SAB5600047
兔抗BRAF (V600E)单克隆抗体
recombinant, expressed in HEK 293 cells, clone RM8, purified immunoglobulin
别名:
Anti-B-RAF1, Anti-B-raf, Anti-BRAF-1, Anti-BRAF1, Anti-NS7, Anti-RAFB1
登录查看公司和协议定价
选择尺寸
1 EA
CN¥7,907.62
CN¥7,907.62
国内现货，预计发货时间April 14, 2025详情
所有图片(3)
选择尺寸
变更视图
1 EA
CN¥7,907.62
About This Item
UNSPSC代码:
12352203
NACRES:
NA.41
CN¥7,907.62
国内现货，预计发货时间April 14, 2025详情
推荐产品
重组
expressed in HEK 293 cells
质量水平
抗体形式
purified immunoglobulin
抗体产品类型
primary antibodies
克隆
RM8, monoclonal
recombinant monoclonal
表单
buffered aqueous glycerol solution
种属反应性
human
浓度
~1 mg/mL
技术
ELISA: 0.5-2 μg/mL
immunoblotting: 0.5-2 μg/mL
immunocytochemistry: 0.5-5 μg/mL
immunohistochemistry: 0.5-5 μg/mL
同位素/亚型
IgG
一般描述
BRAF（B-Raf 原癌基因）是一种丝氨酸-苏氨酸激酶，编码 B-Raf 蛋白。它位于人类染色体7q34上。
特异性
该抗体与BRAF V600E突变体反应。与野生型BRAF无交叉反应。
免疫原
对应于BRAF V600E突变体的肽
生化/生理作用
BRAF（B-Raf 原癌基因）参与细胞生长的直接信号传导。它通过在皮肤黑色素瘤、甲状腺癌和结肠癌等各种肿瘤中启动丝裂原活化蛋白激酶 (MAPK) 途径，诱导肿瘤生长。
特点和优势
请完全放心地评估我们的抗体。如果抗体在您的研究中无效，我们将全额退款或换货。了解更多。
外形
溶于含有50％甘油、1％BSA和0.09％叠氮化钠的磷酸盐缓冲盐水中。
免责声明
除非我们的产品目录或产品附带的其他公司文档另有说明，否则我们的产品仅供研究使用，不得用于任何其他目的，包括但不限于未经授权的商业用途、体外诊断用途、离体或体内治疗用途或任何类型的消费或应用于人类或动物。
未找到合适的产品？
试试我们的产品选型工具.
储存分类代码
10 - Combustible liquids
WGK
WGK 2
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
常规特殊物品
含少量动物源组分生物产品
Maria Russi et al.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 180, 106311-106311 (2022-10-24)
Two clinically approved anticancer drugs targeting BRAF in melanoma patients - dabrafenib (DAB) and vemurafenib (VEM) - have been successfully encapsulated into nanomicelles formed upon self-assembly of an amphiphilic dendrimer AD based on two C18 aliphatic chains and a G2
Daniel Delev et al.
Scientific reports, 10(1), 96-96 (2020-01-11)
Long-term epilepsy-associated tumors (LEATs) represent mostly benign brain tumors associated with drug-resistant epilepsy. The aim of the study was to investigate the specific transcriptional signatures of those tumors and characterize their underlying oncogenic drivers. A cluster analysis of 65 transcriptome
Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study.
Shinozaki E, et al.
British Journal of Cancer, 117(10), 1450-1450 (2017)
The significance of BRAF V600E mutation status discordance between primary cutaneous melanoma and brain metastases: The implications for BRAF inhibitor therapy.
Hannan EJ, et al.
Medicine, 96(48), e8404-e8404 (2017)
Xuhong Wang et al.
Oncology letters, 18(1), 927-935 (2019-07-11)
Keratin 19 (KRT19) is a type I cytokeratin that serves an important role in multiple types of cancer; however, little is known regarding its role in thyroid cancer. Therefore, the aim of the current study was to investigate the role
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持
